recessive dlsorder of Iron metabolism that 1s estimated to affect approximately 1 In 300 ~nd~vlduals of northern European orlgln Several mlssense mutations have been reported In the H E gene lncludlng C282Y accounting for 80% to 90% of HH chromosomes. H63D whlch hds been found on 40% to 70% of non-C282Y HH chromosomes, and S65C whlch has been found on 5% to 10% of non-C282Y HH chromosomes In a d d~t~o n , HFE slngle nucleot~de polymorph~sms (SNPs) have heen ~dentlfled, lncludlng 5569GlA In lntron 4 We analyzed 336 unrelated lndlvlduals that had been referred for hered~tary hemochromatos~s molecular testlng Each sample was tested for C282Y. H63D. S65C dnd 5569GIA status, and data were comp~led reldtlve to cllnlcal status All sequence varlants appeared to be In l~nkage dlsequ~l~brlum such that there were no ~nd~vlduals wlth any comb~nat~on of more than two of these nucleot~de changes Allele frequenc~es for Y282. D63, and C65 wure slgn~f~cantly greater In cl~nlcally affected lnd~vlduals (as ha5 hecn previously reported) whereas the frequency of the 5569A dlslc. \ L J a s~g n~f~c a n t l y elevated In unaffected l n d l v~d u~l s In our p o p u l~t~o n (I' < 0 000001) These f~n d~n g s suggest that 5569GlA genotype screenlnf can hc used to mod~fy the probdbll~ty of HH when mutatlon screening results a e ~nconclus~ve Niemann-Pick Type C (NPC) disease is an autosomal recessive lysosornal storage dlsorder that is character~zed b~ochernically by sequestration of unesterified cholesterol and glycolipids in endosomal andlor lysosomal vesicles with consequent delay in cholesterol esterification. Clinical manifestations include progressive neurodegeneration, variable hepatosplenomegaly and vertical supranuclear gaze palsy. Death often occurs during childhood or early adulthood. NPC is a panethnic disorder with an estimated prevalence of I in 150.000. In approximately 95% of families the disease is l~nked to the NPC-I gene at 18qll. This gene, isolated in 1997, contains 25 exons encoded by 3.9kb cDNA. Using multiplex PCR and CSGE to screen for mutations in NPC-I, we have tested genomic DNA from 53 unrelated affected individuals. Putative mutations were identified on 64 of 108 (59%) d~sease alleles and ~ncluded 38 different DNA alterat~ons located throughout the gene. Types of mutations included: missense (27). nonsense (I), frameshift ( 3 , in-frame deletion (2) and splice site mutatlon (3). Recurrent mutations were 1106 IT (allele frequency 191108, 18%). P237S (allele frequency 41108, 3.76). and dell271 (allele frequency 2l108, 1.9%). In add~tlon to the putative mutations, 6 polymorphisrns were identified. The find~ng of a h~gh degree of mutation heterogeneity with many missense alterations creates difficulties for the clinical application of mutation testing in NPC. Although we can determ~ne if mlssense alterations are in proposed functional doma~ns or at sltes conserved across species, we cannot be certain of the pathogenic~ty of such alterations. DNA alterat~ons identified in affected patlents can be used as l~nkage markers to determine camer status of at risk relatives. However, the d~agnosis in the affected ind~vidual must be confirmed by b~ochemical testing, and must include complementation analysis to establ~sh that the defect is In NPC-I Mutation analysis for individuals from the general population (e.g. partners of NPC carriers) is likely to result in s~gn~ficant d~lemrnas In interpretation of results. Funded by a grant from the Ara Pdrsegh~an Med~cal Research Foundation. Mohr Tranebjaerg syndrome (MIM 304700) is clinically well characterized and shown to be due to frameshiWstop mutations in the DDP gene (Tranebjaerg L et al, J Med Genet 32; 257-263, 1995; Jin H et al, Nat Genet 14; 177-180, 1996) . We present the updated spectrum of mutations in the 7 families recognized from Norway, USA, Spain, Denmark, Australia and the Netherlands each having a private DDP mutation. Recently, a DDP hornologue (TIM 8) in yeast was shown to be involved in mitochondrial membrane protein transport (Koehler C et al, PNAS; 99: 2141 -6, 1999 which implies that human deafness-dystonia syndrome is likely to be a mitochondrial dysfunction associated with neurodegenerative disease. We present clinical neuropathological and biochemical evidence supporting that this human deafness-optic atrophy-dystcnia syndrome is caused by mitochondrial dysfunction.
Mohr-Tranebjaerg Syndrome is an X-linked Recessive Disorder

